Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 5380792, 8 pages
http://dx.doi.org/10.1155/2016/5380792
Research Article

Metabolic Syndrome and Selective Inflammatory Markers in Psoriatic Patients

1Department of Dermatology and Venereology, University Hospital Hradec Kralove, 50005 Hradec Kralove, Czech Republic
2Institute of Clinical Immunology and Allergology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, 50038 Hradec Kralove, Czech Republic
3Department of Transfusion Medicine, University Hospital Hradec Kralove, 50005 Hradec Kralove, Czech Republic
4Department of Medical Biophysics, Faculty of Medicine in Hradec Kralove, Charles University in Prague, 50038 Hradec Kralove, Czech Republic
5Institute of Hygiene and Preventive Medicine, Faculty of Medicine in Hradec Kralove, Charles University in Prague, 50038 Hradec Kralove, Czech Republic
6Institute of Pathological Physiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, 50038 Hradec Kralove, Czech Republic

Received 13 September 2016; Revised 11 November 2016; Accepted 30 November 2016

Academic Editor: Margarete D. Bagatini

Copyright © 2016 Simona Vachatova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Parisi, D. P. M. Symmons, C. E. M. Griffiths, and D. M. Ashcroft, “Global epidemiology of psoriasis: a systematic review of incidence and prevalence,” Journal of Investigative Dermatology, vol. 133, no. 2, pp. 377–385, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Deng, C. Chang, and Q. Lu, “The inflammatory response in psoriasis: a comprehensive review,” Clinical Reviews in Allergy & Immunology, vol. 50, no. 3, pp. 377–389, 2016. View at Publisher · View at Google Scholar
  3. L. Borska, C. Andrys, J. Krejsek et al., “Serum level of antibody against benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts in people dermally exposed to PAHs,” Journal of Immunology Research, vol. 2014, Article ID 834389, 6 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Machado-Pinto, M. d. Diniz, and N. C. Bavoso, “Psoriasis: new comorbidities,” Anais Brasileiros de Dermatologia, vol. 91, no. 1, pp. 8–14, 2016. View at Publisher · View at Google Scholar
  5. I. Grozdev, N. Korman, and N. Tsankov, “Psoriasis as a systemic disease,” Clinics in Dermatology, vol. 32, no. 3, pp. 343–350, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. B. B. Davidovici, N. Sattar, P. C. Jörg et al., “Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions,” Journal of Investigative Dermatology, vol. 130, no. 7, pp. 1785–1796, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. U. Praveenkumar, S. Ganguly, L. Ray, S. K. Nanda, and S. Kuruvila, “Prevalence of metabolic syndrome in psoriasis patients and its relation to disease duration: a hospital based case-control study,” Journal of Clinical and Diagnostic Research, vol. 10, no. 2, pp. WC01–WC05, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. M. A. Alsufyani, A. K. Golant, and M. Lebwohl, “Psoriasis and the metabolic syndrome,” Dermatologic Therapy, vol. 23, no. 2, pp. 137–143, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Xu and Y.-H. Zhang, “Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies,” British Journal of Dermatology, vol. 167, no. 6, pp. 1345–1350, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Abuabara, R. S. Azfar, D. B. Shin, A. L. Neimann, A. B. Troxel, and J. M. Gelfand, “Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.,” British Journal of Dermatology, vol. 163, no. 3, pp. 586–592, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Coimbra, C. Catarino, and A. Santos-Silva, “The triad psoriasis-obesity-adipokine profile,” Journal of the European Academy of Dermatology and Venereology, vol. 30, no. 11, pp. 1876–1885, 2016. View at Publisher · View at Google Scholar
  12. S. Galic, J. S. Oakhill, and G. R. Steinberg, “Adipose tissue as an endocrine organ,” Molecular and Cellular Endocrinology, vol. 316, no. 2, pp. 129–139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Ronti, G. Lupattelli, and E. Mannarino, “The endocrine function of adipose tissue: an update,” Clinical Endocrinology, vol. 64, no. 4, pp. 355–365, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Wolk and R. Sabat, “Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations,” Reviews in Endocrine and Metabolic Disorders, pp. 1–13, 2016. View at Publisher · View at Google Scholar
  15. A. Chiricozzi, A. Raimondo, S. Lembo et al., “Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity,” Expert Review of Clinical Immunology, vol. 12, no. 12, pp. 1299–1308, 2016. View at Publisher · View at Google Scholar
  16. E. Moutzouri, V. Tsimihodimos, and A. D. Tselepis, “Inflammatory biomarkers and cardiovascular risk assessment. Current knowledge and future perspectives,” Current Pharmaceutical Design, vol. 19, no. 21, pp. 3827–3840, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Litvinova, D. Atochin, M. Vasilenko et al., “Role of adiponectin and proinflammatory gene expression in adipose tissue chronic inflammation in women with metabolic syndrome,” Diabetology & Metabolic Syndrome, vol. 6, no. 1, article 137, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), “Third report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report,” Circulation, vol. 106, no. 25, pp. 3143–3421, 2002. View at Google Scholar
  19. E. Malkic Salihbegovic, N. Hadzigrahic, and A. J. Cickusic, “Psoriasis and metabolic syndrome,” Medical Archives, vol. 69, no. 2, pp. 85–87, 2015. View at Publisher · View at Google Scholar
  20. A. Baran, I. Flisiak, J. Jaroszewicz, and M. Swiderska, “Serum adiponectin and leptin levels in psoriatic patients according to topical treatment,” Journal of Dermatological Treatment, vol. 26, no. 2, pp. 134–138, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Balci, D. D. Balci, Z. Yonden et al., “Increased amount of visceral fat in patients with psoriasis contributes to metabolic syndrome,” Dermatology, vol. 220, no. 1, pp. 32–37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Naito and S. Imafuku, “Distinguishing features of body mass index and psoriasis in men and women in Japan: a hospital-based case-control study,” The Journal of Dermatology, vol. 43, no. 12, pp. 1406–1411, 2016. View at Publisher · View at Google Scholar
  23. C. Ryan and B. Kirby, “Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities,” Dermatologic Clinics, vol. 33, no. 1, pp. 41–55, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Visser, L. M. Bouter, G. M. McQuillan, M. H. Wener, and T. B. Harris, “Elevated C-reactive protein levels in overweight and obese adults,” The Journal of the American Medical Association, vol. 282, no. 22, pp. 2131–2135, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Kondelkova, L. Borska, C. Andrys et al., “Selected inflammatory and metabolic markers in psoriatic patients treated with goeckerman therapy,” Mediators of Inflammation, vol. 2015, Article ID 979526, 8 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Coimbra, H. Oliveira, F. Reis et al., “C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy,” Journal of the European Academy of Dermatology and Venereology, vol. 24, no. 7, pp. 789–796, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Beygi, V. Lajevardi, and R. Abedini, “C-reactive protein in psoriasis: a review of the literature,” Journal of the European Academy of Dermatology and Venereology, vol. 28, no. 6, pp. 700–711, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Coban, L. Tasli, S. Turgut, S. Özkan, M. T. Ata, and F. Akn, “Association of adipokines, insulin resistance, hypertension and dyslipidemia in patients with psoriasis vulgaris,” Annals of Dermatology, vol. 28, no. 1, pp. 74–79, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. A. R. Vadakayil, S. Dandekeri, S. M. Kambil, and N. M. Ali, “Role of C-reactive protein as a marker of disease severity and cardiovascular risk in patients with psoriasis,” Indian Dermatology Online Journal, vol. 6, no. 5, pp. 322–325, 2015. View at Publisher · View at Google Scholar
  30. A. H. Berg and P. E. Scherer, “Adipose tissue, inflammation, and cardiovascular disease,” Circulation Research, vol. 96, no. 9, pp. 939–949, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Ouchi, S. Kihara, T. Funahashi, Y. Matsuzawa, and K. Walsh, “Obesity, adiponectin and vascular inflammatory disease,” Current Opinion in Lipidology, vol. 14, no. 6, pp. 561–566, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. L. F. Van Gaal, I. L. Mertens, and C. E. De Block, “Mechanisms linking obesity with cardiovascular disease,” Nature, vol. 444, no. 7121, pp. 875–880, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Seven, “Overweight, hypertension and cardiovascular disease: focus on adipocytokines, insulin, weight changes and natriuretic peptides,” Danish Medical Journal, vol. 62, no. 11, p. B5163, 2015. View at Google Scholar
  34. Y. Iwashima, T. Katsuya, K. Ishikawa et al., “Hypoadiponectinemia is an independent risk factor for hypertension,” Hypertension, vol. 43, no. 6, pp. 1318–1323, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. J. Oh, H. K. Lim, J. H. Choi, J. W. Lee, and N. I. Kim, “Serum leptin and adiponectin levels in Korean patients with psoriasis,” Journal of Korean Medical Science, vol. 29, no. 5, pp. 729–734, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Campanati, G. Ganzetti, K. Giuliodori et al., “Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-α inhibitors: results of a retrospective analysis,” International Journal of Dermatology, vol. 54, no. 7, pp. 839–845, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Johnston, S. Arnadottir, J. E. Gudjonsson et al., “Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation,” British Journal of Dermatology, vol. 159, no. 2, pp. 342–350, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Kaur, K. Zilmer, C. Kairane, M. Kals, and M. Zilmer, “Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis,” British Journal of Dermatology, vol. 159, no. 6, pp. 1364–1367, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Kaur, K. Zilmer, V. Leping, and M. Zilmer, “The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 25, no. 11, pp. 1328–1333, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Gerdes, S. Osadtschy, M. Rostami-Yazdi, N. Buhles, M. Weichenthal, and U. Mrowietz, “Leptin, adiponectin, visfatin and retinol-binding protein-4—mediators of comorbidities in patients with psoriasis?” Experimental Dermatology, vol. 21, no. 1, pp. 43–47, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Özdemir, M. Yüksel, H. Gökbel, N. Okudan, and I. Mevlitoğlu, “Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporin,” Journal of Dermatology, vol. 39, no. 5, pp. 443–448, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Badoer, S. Kosari, and M. J. Stebbing, “Resistin, an adipokine with non-generalized actions on sympathetic nerve activity,” Frontiers in Physiology, vol. 6, article 321, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. M. D. Klok, S. Jakobsdottir, and M. L. Drent, “The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review,” Obesity Reviews, vol. 8, no. 1, pp. 21–34, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. A. A. Çerman, S. Bozkurt, A. Sav, A. Tulunay, M. O. Elbaşi, and T. Ergun, “Serum leptin levels, skin leptin and leptin receptor expression in psoriasis,” British Journal of Dermatology, vol. 159, no. 4, pp. 820–826, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Zhou, Y. Li, T. Xia, S. Feng, X. Chen, and Z. Yang, “Resistin overexpression impaired glucose tolerance in hepatocytes,” European Cytokine Network, vol. 17, no. 3, pp. 189–195, 2006. View at Google Scholar · View at Scopus
  46. M. Filková, M. Haluzík, S. Gay, and L. Šenolt, “The role of resistin as a regulator of inflammation: implications for various human pathologies,” Clinical Immunology, vol. 133, no. 2, pp. 157–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Takahashi, H. Tsuji, M. Honma, A. Ishida-Yamamoto, and H. Iizuka, “Increased plasma resistin and decreased omentin levels in Japanese patients with psoriasis,” Archives of Dermatological Research, vol. 305, no. 2, pp. 113–116, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. M. C. Kizilarslanoğlu, Ö. Kara, Y. Yeşil et al., “Alzheimer disease, inflammation, and novel inflammatory marker: resistin,” Turkish Journal of Medical Sciences, vol. 45, no. 5, pp. 1040–1046, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Huang, E. Shen, S. Tang et al., “Increased serum resistin levels correlate with psoriasis: a meta-analysis,” Lipids in Health and Disease, vol. 14, article 44, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. A. D. Tselepis, “Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role,” Journal of Biomedical Research, 2016. View at Publisher · View at Google Scholar
  51. F. D. Kolodgie, A. P. Burke, K. S. Skorija et al., “Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 11, pp. 2523–2529, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. B. L. Cucchiara, S. R. Messe, L. Sansing et al., “Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA,” Stroke, vol. 40, no. 7, pp. 2332–2336, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Thompson, P. Gao, L. Orfei et al., “Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies,” The Lancet, vol. 375, no. 9725, pp. 1536–1544, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Tsimikas, J. Willeit, M. Knoflach et al., “Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study,” European Heart Journal, vol. 30, no. 1, pp. 107–115, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Holzer, P. Wolf, S. Curcic et al., “Psoriasis alters HDL composition and cholesterol efflux capacity,” Journal of Lipid Research, vol. 53, no. 8, pp. 1618–1624, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Holzer, P. Wolf, M. Inzinger et al., “Anti-psoriatic therapy recovers high-density lipoprotein composition and function,” Journal of Investigative Dermatology, vol. 134, no. 3, pp. 635–642, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. S. O'Neill and L. O'Driscoll, “Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies,” Obesity Reviews, vol. 16, no. 1, pp. 1–12, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Rajappa, S. Rathika, M. Munisamy, L. Chandrashekar, and D. M. Thappa, “Effect of treatment with methotrexate and coal tar on adipokine levels and indices of insulin resistance and sensitivity in patients with psoriasis vulgaris,” Journal of the European Academy of Dermatology and Venereology, vol. 29, no. 1, pp. 69–76, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. K.-J. Zhu, C. Zhang, M. Li, C.-Y. Zhu, G. Shi, and Y.-M. Fan, “Leptin levels in patients with psoriasis: a meta-analysis,” Clinical and Experimental Dermatology, vol. 38, no. 5, pp. 478–483, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. R. C. Li, P. Krishnamoorthy, S. Derohannessian et al., “Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors,” Clinical and Experimental Dermatology, vol. 39, no. 1, pp. 19–24, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Coimbra, H. Oliveira, F. Reis et al., “Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy,” Journal of the European Academy of Dermatology and Venereology, vol. 24, no. 12, pp. 1386–1394, 2010. View at Publisher · View at Google Scholar · View at Scopus